Korsana Biosciences (KRSA) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Schrodinger (SDGR) over the past year, gaining 262.5% versus a gain of 39.2%. Over five years, SDGR leads with a -42.0% price change compared with -89.0% for KRSA. Schrodinger is the larger company by market cap ($1.72 billion vs $1.71 billion), about 1.0 times the size.
Schrodinger converts more of its revenue into profit, with a net margin of -40.4% versus -170.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRSA | SDGR |
|---|---|---|
| Share price | $37.56 | $22.93 |
| Market cap | $1.71B | $1.72B |
| 1-day change | +5.95% | -12.95% |
| YTD return | +322.50% | +28.24% |
| 1-year return | +262.55% | +39.22% |
| 5-year return | -89.05% | -42.01% |
| EPS (TTM) | $-16.14 | $-0.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.07M | $255.87M |
| Revenue growth (YoY) | +3.70% | +23.29% |
| Net income (latest FY) | $-3.53M | $-103.27M |
| Gross margin | — | 55.74% |
| Operating margin | -239.78% | -65.23% |
| Net margin | -170.11% | -40.36% |
| 52-week high | $59.36 | $34.00 |
| 52-week low | $7.19 | $10.95 |
| Distance from 52-week high | -36.73% | -32.56% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +17.15% | +46.40% |
| Average volume | 119.71K | 2.08M |
| Shares outstanding | 45.54M | 65.91M |
| Employees | 19 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed SDGR by 223.3 percentage points over the past year.
- Schrodinger is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -170.1 cents for Korsana Biosciences.
- Schrodinger grew revenue faster in its latest fiscal year (+23.29% vs +3.70%).
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
KRSA vs SDGR FAQ
Which is bigger, Korsana Biosciences or Schrodinger?
Schrodinger (SDGR) is larger, with a market capitalization of $1.72B compared with $1.71B for Korsana Biosciences (KRSA).
Which stock has performed better over the past year, KRSA or SDGR?
KRSA returned +262.55% over the past 12 months, compared with +39.22% for SDGR (price return, excluding dividends). Past performance does not predict future results.
Are Korsana Biosciences and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.